AI Terminal
Spexis AG
Report Publication Announcement • May 19, 2022
957_rns_2022-05-19_8c944f29-d913-430c-81df-5cf9534ab996.html
Report Publication Announcement
Open in ViewerOpens in native device viewer
News Details
Corporate | 19 May 2022 07:30
Spexis to present at H.C. Wainwright Global Investment Conference
Spexis AG / Key word(s): Conference
Spexis to present at H.C. Wainwright Global Investment Conference
19.05.2022 / 07:30
Allschwil, Switzerland, May 19, 2022
Spexis to present at H.C. Wainwright Global Investment Conference
Spexis AG (SIX: SPEX) today announced that the company will present at the H.C. Wainwright Global Investment Conference, taking place May 23-26, 2022, in Miami Beach, FL, USA and virtually. Jeff Wager, CEO of Spexis, will provide an overview of the company and its pipeline and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
The in-person presentation will be on Tuesday, May 24 th at 3 PM EDT. Conference details will be available on the Spexis website in the Investor Relations section here .
For further information please contact:
| For Investors: Hernan Levett Chief Financial Officer Spexis AG. +41 61 567 16 00 [email protected] Raimund Gabriel MC Services [email protected] Ph: +49 89 210 228 0 |
For Media: Dr. Stephan Feldhaus Feldhaus & Partner +41 79 865 92 56 [email protected] Dr. Brigitte Keller/Laurie Doyle MC Services [email protected] Europe: +49 89 210 228 0 U.S.: +1 339 832 0752 |
About Spexis
Spexis is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on rare diseases and oncology. The current pipeline of the company is a combination of two legacy companies, Polyphor AG and EnBiotix, Inc. (Boston, MA, USA) which merged in December 2021. The combined company has been renamed to Spexis AG and is trading on the SIX Swiss Exchange under the symbol SIX:SPEX. For further information please visit: www.spexisbio.com .
Disclaimer
This press release contains forward-looking statements which are based on current assumptions and forecasts of Spexis management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Spexis’ results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only as of the date of this communication. Spexis disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.
End of Media Release
| Language: | English |
| Company: | Spexis AG |
| Hegenheimermattweg 125 | |
| 4123 Allschwil | |
| Switzerland | |
| Phone: | +41 61 567 1600 |
| Fax: | +41 61 567 1601 |
| E-mail: | [email protected] |
| Internet: | www.spexisbio.com |
| ISIN: | CH0106213793 |
| Valor: | SPEX |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1356137 |
| End of News | EQS News Service |